Foquest · DIN 02470306 · 35 mg · CR capsule
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Foquest · DIN 02470306
Manufacturer: Elvium Life Sciences; listing date 2023-04-28
Health Canada: Marketed since 2020-09-08 · brand FOQUEST · ATC N06BA04 METHYLPHENIDATE · form Capsule (controlled-release) · route Oral · ingredients METHYLPHENIDATE HYDROCHLORIDE 35 MG · company Elvium life sciences · schedule Controlled drugs (cdsa iii)
Foquest: Formulary list price $3.34 per unit (the source does not state the unit; exact figure $3.3388). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02470306)
Source record
DIN 02470306: Foquest
Raw flags: sec3=Y
Item: 282000081; group id 516; item number 1378; lccId None; manufacturer id ELV
Source form: CR Cap; strength: 35mg
Recorded listing: General benefit
Source prices (unrounded): $3.3388; ministry $3.3388
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02470306
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95928
Therapeutic Notes (formulary)
Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has/have a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Shortage status: not checked (no credentials)